U.S. Markets close in 6 hrs 24 mins

Accuray Incorporated (ARAY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.075-0.08 (-1.81%)
As of 9:36AM EDT. Market open.
People also watch
HNSNANGOVARABMDATEC
  • This fabulous little company with its terrific products is a ripe plumb ready for picking. A larger, deep-pocketed medical instruments outfit can do a better job of marketing their products and dramatically increasing the bottom line.
  • the slow drumbeat of yet another new low. They need to get new management.
  • will this company be around in couple of quarters? I hear the CEO trying to sell its Cyberknife division to raise cash. any comments?
  • May 3, 2017
    CyberKnife provides effective treatment for early stage breast cancer patients

    SEE: http://medicalphysicsweb.org/cws/article/newsfeed/68656

    CyberKnife | Accuray
    The CyberKnife System is a non-invasive1 treatment for cancerous and non-cancerous tumors and other conditions where radiation therapy is indicated. It is used to treat conditions throughout the body, including tumors of the prostate, lung, brain, sp
    www.accuray.com
  • Kind of a financial disaster. Even if they were acquired at a premuim the stock probably would break $5.
  • That's 4 quarters in a row that ARAY has missed earnings! Obviously, Levine has not been able to take the company on a positive path. Besides a complete change in leadership, I don't know what else could be done to turn this company around.
  • More pathetic results. Levine is a failure.
  • a little higher volume 1.1 million,,,hummmm
  • either they didn't get the class A license or they will announce at CC next week.
  • Imagehiratzuka
  • Imageduke-of-bretagne
  • Imageteamniinochska
  • First Cancer Patients in Africa Treated with the TomoTherapy® System|
    Today, 7:32 AM
    You

    Accuray Incorporated has added a news release to its Investor Relations website.

    Title: First Cancer Patients in Africa Treated with the TomoTherapy® System

    Date(s): 11-Apr-2017 7:30 AM

    For a complete listing of our news releases, please click here

    Premier Algerian Cancer Center Now Provides Cancer Patients with Leading-Edge Radiation Treatments
    SUNNYVALE, Calif., April 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the newly built Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria is now treating cancer patients with the first TomoTherapy® Systems installed in Africa. The TomoTherapy System is recognized worldwide for providing highly precise treatments for a broad range of cancer cases, from routine to complex. The first treatment was successfully delivered in February 2017 to a patient with breast cancer.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

    The TomoTherapy Systems are two out of three Accuray systems to be installed and operated at the Center, located not far from the Technoparc of Sidi Abdellah in the suburbs of Algiers. The Radiotherapy and Medical Oncology Center also purchased one CyberKnife® M6TM System which is scheduled to be installed by the end of 2018. With the two systems - CyberKnife and TomoTherapy - in one location, the Center will have the flexibility to efficiently and effectively treat virtually all patients who may benefit from this highly precise form of radiation therapy.

    "We are honored that the Radiotherapy and Medical Oncology Center team has selected the Accuray systems to expand their cancer treatment options. Their decision reinforces growing global recognition of the importance of radiation therapy in treating cancer," said Lionel Hadjadjeba, MD, Corporate Senior Vice President and President of Worldwide Commercial Operations at Accuray. "The TomoTherapy and CyberKnife Systems provide an optimal combination of efficacy and safety while minimizing the impact of treatment on daily lives, and will enable the clinical team to confidently provide each cancer patient with a treatment program that addresses his or her individual needs."

    In Algeria, 45,000 new cases of cancer are diagnosed each year [1]. The acquisition of these new technologies is in accordance with the Algerian Cancer Plan 2015-2019 which, among other measures, aims to improve the performance of radiotherapy services, shorten times to obtain radiotherapy appointments, and improve the quality and safety of care in radiotherapy [1].

    "I am very pleased and proud to offer, at the Radiotherapy and Medical Oncology Center of Sidi Abdellah, a full range of treatment options: from chemotherapy to brachytherapy and now, treatment with the TomoTherapy System. With this leading-edge and innovative radiation therapy device, we can deliver precise, safe and individualized radiation treatments to a wide range of tumor types while preserving surrounding healthy tissue," said Prof. Mustapha Yaker, Director of the Radiotherapy and Medical Oncology Center of Sidi Abdellah. "Maintaining the patient's quality of life during and post-treatment is a top priority and I believe the TomoTherapy System will help us accomplish this goal."

    Based on a CT scanner platform, the TomoTherapy System provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles. These unique features, combined with daily 3D image guidance, enable physicians to deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients. The TomoTherapy System is capable of treating all standard radiation therapy indications including breast, prostate, lung and head and neck cancers, in addition to complex treatments such as total marrow irradiation.

    The CyberKnife System delivers radiosurgery and stereotactic body radiation therapy (SBRT), enabling precise, high quality dose distributions to be confidently administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. Using its unique robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision.
  • As a long suffering owner of Accuray since its IPO in 2007, I can admit that my faith in the ability of management to maximize the value of Accuray's technology has been misplaced. I believe I have been more than patient (close to ten years), buying more shares and averaging down because I believed in the company's technology and future. It is time for management to do the right thing. Hire the right company or companies to put the company up for sale to the highest bidder. Get the best price you can so long-time shareholders like myself can see some sort of meaningful increase in price per share before I take my losses. There are some "hopeless" optimists on this message board who will disagree with my opinion. That is their right.
  • accumulation of this stock
  • If we are to go off the performance % (quarter|performance % (q)|performance (quarter)} which is 3.06%, then you could argue that a pull back on ARAY next day or so could occur before rallying up. Yo you should really check out awesome-STOCKS, they seem on point with their stocks.
  • Good grief what is an Aray shareholder to do? oh that's right buy more!
  • Lifting the medical device tax may raise S/P
  • ARAY is a cornered mouse now. below $4.88 it will start making new lows. above $5.63 is a breakout. on a closing basis for this month.
  • OUTLOOK LOOKS GOOD FOR cYBERKNIFE & OTHER MEDICAL ROBOTS

    Medical Robots Market by Product (Instruments & Accessories and Robot Systems (Surgical Robots, Rehabilitation Robots, Hospital Robots, Non-invasive Surgery Robots)), Application (Orthopedic, Laparoscopy, Neurology) - Global Forecasts to 2021
    By: marketsandmarkets.com
    Publishing Date: February 2017
    Report Code: MD 2257

    request for customization Speak to Analyst Enquiry Before Buying purchase report download pdf request for customization

    Report DescriptionTable of ContentSummaryRequest Sample
    The medical robots market is projected to reach USD 12.80 Billion by 2021 from USD 4.90 Billion in 2016, growing at a CAGR of 21.1% during the forecast period. The growth of the overall market can be attributed to the issuance of IPOs by medical robot companies, advantages offered by robot-assisted training in rehabilitation therapy, growing hospital investments in medical robots, increasing funding for medical robot research, and technological advancements in the field of medical robots.

    In the coming years, the market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in the region can be attributed to the growth in the number of approvals of robots for medical use in Japan, rising prevalence of cancers in China, growing robotic procedures backed by rising number of hospital beds in India, rising adoption of medical robots in Asia, funding collaborations across the Asian region, and training programs in Australia.

    On the basis of product, the market is segmented into instruments & accessories and medical robot systems. The medical robot systems segment is further fragmented into surgical robots, rehabilitation robots, noninvasive radiosurgery robotic systems, hospital & pharmacy robots, and other medical robotic systems (capsule robots and robots for emergency medicine). In 2016, the surgical robots segment is expected to command the largest share of medical robot systems. However, the rehabilitation robot systems are likely to grow at the highest CAGR during the forecast period.

    On the basis application, the medical robots market is segmented into laparoscopy, orthopedics, neurology, special education, and other applications (gynecology, urology, cardiology, and nanomedicine). The neurology application segment is expected to grow at the highest CAGR during the forecast period. However, the laparoscopy segment is estimated to command the largest share of the market, by application in 2016.

    In 2016, North America is expected to account for the largest share of the global medical robots market. North America’s leadership in the market can be attributed to can be attributed to favorable reimbursement scenario in the U.S., funding by the U.S. Department of Defense, grants from NSF for research activities in the U.S, rising venture capital investments in the U.S., government support in Canada, and increasing medical robot purchases backed by rising preference for minimally invasive surgeries.

    Key players in the global medical robots market include Intuitive Surgical, Inc. (U.S.), Stryker Corporation (U.S.), Mazor Robotics Ltd. (Israel), Hocoma AG (Switzerland), Hansen Medical Inc. (U.S.), Accuray Incorporated (U.S.), Omnicell, Inc. (U.S.), Ekso Bionics Holdings, Inc. (U.S.), ARxIUM (U.S.), and Kirby Lester LLC (U.S.).

    Stakeholders of the Medical Robots Market

    Medical Robots and Related Devices Manufacturing Companies
    Suppliers and Distributors of Medical Robot Systems
    Hospitals and Diagnostic Centers
    Ambulatory Surgery Centers
    Academic Centers
    Venture Capitalists
    To know about the assumptions considered for the study, download the pdf brochure

    The scope of the Report:

    This research report categorizes the medical robots market into the following segments:

    Medical Robots Market, by Product

    Instruments & Accessories
    Medical Robot Systems
    Surgical Robots
    Rehabilitation Robots
    Noninvasive Radiosurgery Robots
    Hospital & Pharmacy Robots
    Other Medical Robotic Systems
    Medical Robots Market, by Application

    Laparoscopy
    Orthopedics
    Neurology
    Special Education
    Other Applications
    Medical Robots Market, by Region

    North America
    U.S.
    Canada
    Europe
    EU 5
    Rest of Europe (RoE)
    Asia-Pacific
    Rest of the World (RoW)
    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs.

    The following customization option is available for the report:

    Portfolio Assessment

    Product Matrix, which gives a detailed comparison of product portfolio of top 3 companies

    Company Information

    Detailed analysis and profiling of additional players (up to 5)

    Custom Market Research Services
    We will customize the research for you, in case the report listed above does not meet